Denver, CO, 06/12/2014 (Stocksntrade) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) recently announced that the company has initiated its phase I/IIA clinical-trial to evaluate the safety, immunogenicity & clinical responses of INO-3112,- the immunotherapy product, in the treatment of human papillomavirus- associated head & neck cancer. This drug is a mix of VGX-3100, , INO’s lead active-immunotherapy product, & 12 (IL-12), its proprietary immune-activator expressing interleukin, VGX-3100 is now being evaluated in the randomized Phase-II efficacy-trial for treatment of the high-grade cervical dysplasia.
Very Effective Response
In its Phase-I trial of VGX-3100, INO demonstrated that the immunotherapy produced very high-levels of durable T-cell immune responses, very notably the CD8+ “killer” T cells, in 78 percent of all the patients in this study. The CD8+ T cells indicated functional ability to effectively kill the target cells that display the E6 & E7 antigens. In the preclinical animal-models, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s HPV immunotherapy demonstrated 100 percent protection against the HPV E6 & E7-expressing tumors & prevented/ delayed growth of those tumors. This proprietary IL-12 immune activator- INO-9012 had earlier indicated that it could enhance antigen-specific CD4+ & CD8+ T-cell immune responses to INO’s PENNVAX® HIV-DNA vaccine in its clinical trial.
The Nest Phases
Inclusion of the DNA-based immune-activator in INO-3112 is specifically designed to increase generation of the HPV-specific CD8+ T cells for treatment of the HPV-related cancer. In the open-label study, that is named HPV-005, upto 20 adults suffering from HPV-positive head & neck squamous cell carcinoma will be treated with the company’s INO-3112. They will be followed for safety, immune & the clinical responses. In 1 segment part of this study, upto 10 patients will be treated with the INO-3112 before & after resection of the tumor. In the 2nd pa Less